The purpose of this article is to provide perspective, in the background of various PARP inhibitors for recurrent ovarian cancer treatment, their mechanism of action, tumors’ genomic profiling, accompanied by companion diagnostics, tolerance, and potential resistance mechanisms to PARP inhibitor therapy. The gene discussed is PARP1; the disease is ovarian cancer.